CRISPR Therapeutics AG — AI technical analysis, September 2026
NYSE/NASDAQ · Biotechnology
AI Recommendation
BUY
Technical score 70/100
Last price: $51.83 · 52W range $44.12 – $78.48
Short answer
Should you buy CRSP right now? Stockgaide's AI rates CRSP as
BUY, with a technical score of
70/100 at a last price of $51.83.
The 50-day average is above the 200-day average, and RSI sits at 36.0.
Wall Street's consensus rating is 2.18/5.
Full AI analysis for CRSP
Strategic Conclusion
Recommendation: Buy
Why? The stock is deeply oversold (RSI 25.6) near its 52-week low, while the golden cross (SMA50 > SMA200) signals a potential medium-term uptrend. Analyst consensus is moderately positive (2.18/5, 17 buys, 0 sells), and the technical score is 80/100. The main risk is negative earnings (no P/E) and bearish MACD momentum, but the oversold condition and analyst support suggest a rebound opportunity.
Ideal profile: Short-term trader seeking a bounce; long-term investors should wait for confirmation of a trend reversal.
Price range: Entry zone $50–$52; upside target $58–$60 (SMA50 resistance); stop-loss at $44 (52-week low).
Practical action: Buy now at current levels with a tight stop-loss. Add on a break above $54 (SMA50). Reduce if price closes below $44.
1. Recent Price & Momentum
Current price $51.72 is 34% below the 52-week high ($78.48) and 17% above the 52-week low ($44.12) — closer to the bottom, indicating a downtrend.
The stock has been in a clear decline since the high, but the oversold RSI suggests selling pressure may be exhausted.
Short-term scenarios: A bounce toward $54–$56 is likely if buyers step in; failure to hold $50 could lead to a retest of $44.
2. Valuation (P/E)
P/E is not available (TTM) — typical for biotech with negative earnings. The company is pre-profit, so valuation must be based on pipeline potential and cash position.
The current market cap of $5B reflects significant expectations for CRISPR-based therapies; the price already discounts near-term risks, but no earnings support means high volatility.
3. Technical Analysis
SMA50 ($53.58) > SMA200 ($53.28) — golden cross, but price is below both, so the trend is still bearish in the short term.
MACD (-0.0536) below signal (0.8269) with negative histogram — bearish momentum, but the gap is narrowing.
Technical score: 80/100 → BUY, driven by the golden cross and oversold RSI, despite MACD weakness.
4. Analyst Consensus
Mean rating 2.18/5 (1=strong buy, 5=strong sell) — between "buy" and "hold", leaning positive. Distribution: 17 buy, 11 hold, 0 sell.
Analysts are more optimistic than the price action suggests, aligning with the technical oversold signal. This divergence supports a contrarian buy, but the lack of sell ratings indicates limited downside risk from a fundamental perspective.
Technical signal details
Rule-based read from price and momentum indicators only — the score behind the AI's recommendation above. Technical score: 70/100 (BUY).
50-day moving average is above the 200-day — medium-term uptrend (golden-cross territory).
MACD is below its signal line — bearish momentum.
RSI at 36.03 — neutral momentum.
Wall Street consensus rating of 2.18 — moderately positive.
Stockgaide's AI currently rates CRSP as BUY, with a technical score of 70 out of 100 at a last price of $51.83. This is educational content, not investment advice.
Is CRSP in an uptrend?
CRSP's 50-day moving average (53.43) is above its 200-day moving average (53.29), which points to a medium-term uptrend.
What is CRSP's RSI today?
CRSP has a 14-day RSI of 36.0, which places it in neutral territory (above 70 is overbought, below 30 is oversold).
What do analysts say about CRSP?
Wall Street analysts covering CRSP have a consensus rating of 2.18 out of 5 (1 = Strong Buy), meaning they are moderately positive — 17 Buy · 11 Hold · 0 Sell.
Where is CRSP trading in its 52-week range?
CRSP last traded at $51.83, against a 52-week range of $44.12 to $78.48 — about 22% of the way up that range.
Get the full AI analysis of CRSP
Price targets, fundamentals deep-dive and an AI-written report — free, no signup.